*Jury in Valadez case in
*Verdict is consistent with scientific consensus that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer
*GSK will continue to vigorously defend itself against all other claims
*Next Zantac trial (Williams) due to start in
Prior to this verdict, the court rejected the Plaintiff's ability to request punitive damages.
Separately, the company welcomed the recent court ruling dismissing the next Zantac trial (Williams) that was due to start on
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D "Risk factors" in GSK's Annual Report on Form 20-F for 2023, and GSK's Q1 Results for 2024.
.
(C) 2024 M2 COMMUNICATIONS, source